Press release Stine Krag Brunvold 1/6/25 Press release Stine Krag Brunvold 1/6/25 NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease Read More Press release Stine Krag Brunvold 12/19/24 Press release Stine Krag Brunvold 12/19/24 NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics Read More Press release Stine Krag Brunvold 12/18/24 Press release Stine Krag Brunvold 12/18/24 NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology Read More Events Stine Krag Brunvold 11/30/24 Events Stine Krag Brunvold 11/30/24 ClC-1 inhibition for improvement of muscle function in CMT webinar Read More Press release Stine Krag Brunvold 11/18/24 Press release Stine Krag Brunvold 11/18/24 NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Read More Press release Stine Krag Brunvold 10/11/24 Press release Stine Krag Brunvold 10/11/24 NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Read More Press release Stine Krag Brunvold 7/11/24 Press release Stine Krag Brunvold 7/11/24 NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Read More Press release Stine Krag Brunvold 6/18/24 Press release Stine Krag Brunvold 6/18/24 NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Read More Press release Stine Krag Brunvold 6/11/24 Press release Stine Krag Brunvold 6/11/24 NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Read More Events Stine Krag Brunvold 4/25/24 Events Stine Krag Brunvold 4/25/24 Watch Cure SMA's Clinical Trial Update Webinar with NMD Pharma Read More Press release Stine Krag Brunvold 3/22/24 Press release Stine Krag Brunvold 3/22/24 NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Read More Events Stine Krag Brunvold 3/21/24 Events Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More Press release Stine Krag Brunvold 3/21/24 Press release Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – “My wish for Women: Dare and just go for it” – Sabine Dandiguian, Managing Partner, Jeito, shares her inspiring journey Read More Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – Celebrating all the incredible women at NMD Pharma Read More Press release Stine Krag Brunvold 3/1/24 Press release Stine Krag Brunvold 3/1/24 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Read More Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Read More Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More Older Posts
Press release Stine Krag Brunvold 1/6/25 Press release Stine Krag Brunvold 1/6/25 NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease Read More
Press release Stine Krag Brunvold 12/19/24 Press release Stine Krag Brunvold 12/19/24 NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics Read More
Press release Stine Krag Brunvold 12/18/24 Press release Stine Krag Brunvold 12/18/24 NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology Read More
Events Stine Krag Brunvold 11/30/24 Events Stine Krag Brunvold 11/30/24 ClC-1 inhibition for improvement of muscle function in CMT webinar Read More
Press release Stine Krag Brunvold 11/18/24 Press release Stine Krag Brunvold 11/18/24 NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Read More
Press release Stine Krag Brunvold 10/11/24 Press release Stine Krag Brunvold 10/11/24 NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Read More
Press release Stine Krag Brunvold 7/11/24 Press release Stine Krag Brunvold 7/11/24 NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Read More
Press release Stine Krag Brunvold 6/18/24 Press release Stine Krag Brunvold 6/18/24 NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Read More
Press release Stine Krag Brunvold 6/11/24 Press release Stine Krag Brunvold 6/11/24 NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Read More
Events Stine Krag Brunvold 4/25/24 Events Stine Krag Brunvold 4/25/24 Watch Cure SMA's Clinical Trial Update Webinar with NMD Pharma Read More
Press release Stine Krag Brunvold 3/22/24 Press release Stine Krag Brunvold 3/22/24 NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Read More
Events Stine Krag Brunvold 3/21/24 Events Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More
Press release Stine Krag Brunvold 3/21/24 Press release Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More
Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – “My wish for Women: Dare and just go for it” – Sabine Dandiguian, Managing Partner, Jeito, shares her inspiring journey Read More
Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – Celebrating all the incredible women at NMD Pharma Read More
Press release Stine Krag Brunvold 3/1/24 Press release Stine Krag Brunvold 3/1/24 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Read More
Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Read More
Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More
Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More
Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More
